Agenus Inc. (NASDAQ:AGEN) Sees Significant Increase in Short Interest

Agenus Inc. (NASDAQ:AGEN) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 3,399,217 shares, an increase of 22.5% from the December 15th total of 2,774,043 shares. Based on an average trading volume of 715,032 shares, the short-interest ratio is currently 4.8 days. Currently, 10.6% of the shares of the company are short sold. Currently, 10.6% of the shares of the company are short sold. Based on an average trading volume of 715,032 shares, the short-interest ratio is currently 4.8 days.

Agenus Stock Performance

Shares of AGEN opened at $3.34 on Monday. The firm has a market cap of $113.59 million, a P/E ratio of -1.57 and a beta of 1.58. Agenus has a 52 week low of $1.38 and a 52 week high of $7.34. The firm’s 50-day simple moving average is $3.90 and its 200 day simple moving average is $4.42.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.63 by ($0.69). The business had revenue of $30.24 million for the quarter, compared to analysts’ expectations of $80.39 million. As a group, equities analysts forecast that Agenus will post -12.55 earnings per share for the current year.

Institutional Investors Weigh In On Agenus

Hedge funds and other institutional investors have recently modified their holdings of the company. Traynor Capital Management Inc. acquired a new position in shares of Agenus in the third quarter valued at about $50,000. Catalyst Funds Management Pty Ltd bought a new stake in Agenus in the 2nd quarter valued at about $50,000. Squarepoint Ops LLC acquired a new position in shares of Agenus during the 3rd quarter worth approximately $54,000. Jump Financial LLC bought a new position in shares of Agenus during the second quarter worth approximately $55,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Agenus in the first quarter valued at approximately $58,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on AGEN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agenus in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating on shares of Agenus in a report on Monday, October 20th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Agenus presently has a consensus rating of “Hold” and an average price target of $14.50.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.